« CLMA Annual Meeting in Atlanta Canceled Due to Tornado Damage | Main | President of eClinicalWorks Discusses PHRs and Patient Portals »


bev MD

As a pathologist, I would have a few questions about the sensitivity/specificity of this technique. How would it label cells that we consider "dysplastic' for instance? What would be its false negative rate, risking nonremoval of a cancerous polyp that has invaded by the time of a re-exam? Given the relative ease of resecting most polyps, I can't see much benefit except for saving the pathologist's bill, given that the endoscopist would now charge more using this technique, plus a polyp excision charge for ones deemed "malignant".
Or am I missing something?

The comments to this entry are closed.

Corporate Underwriters



Search Lab Soft News

  • Google


Subscribe to Lab Soft News (Email and RSS Feeds)

Your email address:

Powered by FeedBlitz

May 2020

Sun Mon Tue Wed Thu Fri Sat
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
Blog powered by Typepad
Member since 12/2005